Episode 89 – DOACs Part 2: Bleeding and Reversal Agents

episode

Emergency Medicine Cases not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

How Mikey Madison Prepared For Her Role In The Social Reckoning 48 min · 28 Sep 2026 · The Run-Through with Vogue

Cornell Jane Doe Files Suit (feat. Mark Hamill) 35 min · 28 Sep 2026 · The Daily Beans

Sir Michael Moritz on ‘Auslander,’ Identity and Life as an Outsider 1h 6m · 28 Sep 2026 · On with Kara Swisher

Best of Design Matters: Ada Limón 1h 15m · 28 Sep 2026 · Design Matters with Debbie Millman

LE MEILLEUR DE RUQUIER - Le Belge, les fruits et les noix de coco... L'histoire drôle de Roselyne Bachelot 3 min · 28 Sep 2026 · Les Grosses Têtes

Beans Talk | Netanyahu Addresses the UN 15 min · 28 Sep 2026 · The Daily Beans

Report any issue

Source

Recorded06 Dec 2016

Publisherfeeds.podcastmirror.com ↗

Handlerec:9163293

Show notes

In this Part 2, DOACs Bleeding and Reversal we discuss the management of bleeding in patients taking DOACs with minor risk bleeds, like epistaxis where local control is easy to access, moderate risk bleeds, like stable GI bleeds and high risk bleeds, like intracranial hemorrhage. We answer questions such as: How do we weigh the risks and benefits of stopping the DOAC? When is reversal of the DOAC is advised? How best do we accomplish the reversal of DOACs? Is there any good evidence for the newest reversal agent? When should we stop DOACs for different procedures, and when should we delay the procedure?

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in